GO:1903001 negative regulation of lipid transport across blood-brain barrier: Barrier Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903001 describes any process that stops, prevents or reduces the frequency, rate or extent of lipid transport across the blood-brain barrier (BBB).
• The BBB is a selective interface formed by brain endothelial cells; its lipid handling is dominated by the lysolipid transporter Mfsd2a (MFSD2A), which imports DHA-containing lysophosphatidylcholine and suppresses transcytosis.
• Loss of Mfsd2a increases BBB permeability and lipid transcytosis, linking GO:1903001 to BBB integrity and neurovascular disease.
• Inflammatory signals such as LPS and NF-kB/miRNA-146a/miRNA-155 communication between gut microbiome and brain can modulate BBB transport and lipid-related pathways.
• Nitric oxide isoenzymes regulate BBB transport of insulin, showing that BBB transport is actively controlled by signaling molecules.
• Lipid nanomedicine approaches that inhibit BRD4/PI3K and MDM2/XIAP illustrate how lipid transport and lipid-based delivery intersect with brain tumor therapy.
Description
GO:1903001, negative regulation of lipid transport across blood-brain barrier, is a biological process term that captures the active suppression of lipid movement from blood into the brain parenchyma across the blood-brain barrier (BBB). The BBB is a specialized neurovascular interface that restricts the free exchange of macromolecules and lipids, and its lipid transport properties are essential for brain lipid homeostasis. Understanding this process is important because dysregulated lipid transport across the BBB is associated with altered brain lipid supply, barrier permeability and neuroinflammatory signaling. Researchers study GO:1903001 to identify the molecular brakes that keep lipid transcytosis low and to determine how these brakes fail in disease. The term is also relevant to drug delivery, because strategies that transiently modulate BBB lipid transport can influence brain exposure to lipid-based nanomedicines. In this article, we define GO:1903001, outline its mechanistic basis, list key genes and models, and describe CRISPR-based methods for interrogating it.
negative regulation of lipid transport across blood-brain barrier At A Glance
| GO ID | GO:1903001 |
|---|---|
| GO term | negative regulation of lipid transport across blood-brain barrier |
| Ontology | biological_process |
| Synonym | down regulation of lipid transport across blood brain barrier; down-regulation of lipid transport across blood brain barrier; downregulation of lipid transport across blood brain barrier; inhibition of lipid transport across blood brain barrier; negative regulation of lipid transport across blood brain barrier |
| Major function | Suppression of lipid movement from blood into the brain across the BBB |
| Related transporter | Mfsd2a (MFSD2A), a lysolipid transporter that imports DHA-lysophosphatidylcholine and limits transcytosis |
| Related signaling | Nitric oxide isoenzymes regulate BBB transport of insulin |
| Related inflammation | LPS-stimulated NF-kB, miRNA-146a and miRNA-155 communication between gut microbiome and brain |
| Research relevance | BBB integrity, brain lipid homeostasis, neurovascular disease and brain drug delivery |
What Is GO:1903001?
GO:1903001 is defined by QuickGO as any process that stops, prevents or reduces the frequency, rate or extent of lipid transport across the blood-brain barrier. In practice, it refers to the regulatory mechanisms that actively limit the movement of lipids and lipid-bound cargo from the blood compartment into the brain across the BBB. This includes transporter-mediated lipid uptake, vesicular transcytosis and signaling pathways that suppress these events. The term is a negative regulatory biological process, meaning it describes inhibition or downregulation of lipid transport rather than the transport event itself. Its synonyms include down regulation, down-regulation, downregulation, inhibition and negative regulation of lipid transport across the blood brain barrier.
Why Is negative regulation of lipid transport across blood-brain barrier Important in Cell Biology?
GO:1903001 matters because the BBB is a gatekeeper for brain lipid supply, and its negative regulation determines how much lipid and lipid-associated cargo reaches the brain. When this suppression is lost, increased lipid transcytosis and barrier leakiness can contribute to neurovascular dysfunction and neuroinflammation. Conversely, understanding how to transiently reduce this suppression may improve delivery of lipid-based therapeutics to the brain. Therefore, GO:1903001 sits at the intersection of brain lipid biology, barrier physiology and therapeutic delivery.
• Maintains brain lipid homeostasis by limiting lipid influx across the BBB.
• Preserves BBB integrity by suppressing transcytosis.
• Links gut microbiome-derived inflammatory signals to brain barrier function.
• Provides a target for modulating brain delivery of lipid nanomedicines.
• Relevant to neuroinflammatory conditions where BBB permeability changes.
• Involves signaling molecules such as nitric oxide that regulate BBB transport.
• Helps explain how brain lipid supply is matched to metabolic demand.
• Guides CRISPR screens for regulators of BBB lipid transport.
• Supports development of brain-targeted therapies for tumors such as medulloblastoma.
• Provides a framework for studying transporter-mediated lipid uptake in the brain.
What Happens During negative regulation of lipid transport across blood-brain barrier?
Barrier recognition and lipid cargo selection
In simple terms: The BBB first decides which lipids are allowed to approach the brain.
The BBB is formed by brain endothelial cells that restrict free lipid diffusion. Negative regulation begins with recognition of lipid cargo, such as DHA-containing lysophosphatidylcholine, by specific transporters and binding proteins at the luminal surface. Mfsd2a is a key lysolipid transporter that mediates uptake of DHA-lysophosphatidylcholine and influences lipid transcytosis. This step ensures that only selected lipids are considered for transport, while others are excluded.
Transporter-mediated uptake and transcytosis suppression
In simple terms: Specialized transporters take up some lipids but also keep bulk transcytosis low.
Mfsd2a imports lysolipids into brain endothelial cells and its activity is associated with suppression of transcytosis, thereby limiting lipid movement across the BBB. Loss of Mfsd2a increases BBB permeability and lipid transcytosis, indicating that it is part of the negative regulatory machinery. This step couples lipid uptake to barrier tightening.
Signaling control by nitric oxide and inflammatory pathways
In simple terms: Signals like nitric oxide and inflammatory molecules can dial lipid transport up or down.
Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the BBB, showing that BBB transport is actively controlled by signaling molecules. Inflammatory communication between the gastrointestinal microbiome and the brain involves LPS-stimulated NF-kB, miRNA-146a and miRNA-155, which can modulate BBB-related pathways. These signals can influence the negative regulation of lipid transport across the BBB.
Metabolic and developmental context
In simple terms: The brain's metabolic state and developmental stage shape how much lipid transport is allowed.
Feed restriction alters metabolites in cerebrospinal fluid and plasma of dairy cows, indicating that systemic metabolic status influences brain fluid composition. Developmental expression of cholesterogenic enzymes such as NSDHL and negative selection of NSDHL-deficient cells in the Bpa(1H)/+ mouse shows that lipid synthesis pathways are developmentally regulated. These findings suggest that negative regulation of lipid transport across the BBB is tuned by metabolic and developmental cues.
Key Genes Involved in GO:1903001 negative regulation of lipid transport across blood-brain barrier
The following genes and proteins have been linked to lipid transport, BBB function or related regulatory pathways and are relevant to GO:1903001.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MFSD2A | Lysolipid transporter that imports DHA-lysophosphatidylcholine and suppresses transcytosis | Central to negative regulation of lipid transport across the BBB; KO increases permeability |
| NSDHL | Cholesterogenic enzyme involved in lipid synthesis | Developmental lipid pathway; negative selection of deficient cells |
| NF-kB | Inflammatory transcription factor activated by LPS | Links gut microbiome signals to BBB lipid transport regulation |
| miRNA-146a | Inflammatory microRNA involved in gut-brain communication | Modulates BBB-related inflammatory pathways |
| miRNA-155 | Inflammatory microRNA involved in gut-brain communication | Modulates BBB-related inflammatory pathways |
| BRD4 | Epigenetic reader and therapeutic target in medulloblastoma | Lipid nanomedicine target; intersects with lipid delivery |
| PI3K | Signaling kinase inhibited in medulloblastoma therapy | Lipid nanomedicine co-target; relevant to brain tumor lipid signaling |
| MDM2 | E3 ubiquitin ligase inhibited in medulloblastoma therapy | Lipid nanomedicine co-target |
| XIAP | Apoptosis inhibitor inhibited in medulloblastoma therapy | Lipid nanomedicine co-target |
| Nitric oxide synthase (NOS) isoenzymes | Produce nitric oxide that regulates BBB transport | Modulate LPS-enhanced insulin transport across BBB |
| Insulin receptor | Mediates insulin transport across BBB | Model for BBB transport regulation by nitric oxide |
| Lipoprotein receptors | Mediate lipid uptake at the BBB | Potential regulators of lipid transport |
| ABC transporters | Efflux transporters at the BBB | May contribute to negative regulation of lipid transport |
| Apoptosis regulators | Control cell survival in BBB endothelium | Relevant to barrier integrity |
| Tight junction proteins | Maintain BBB barrier properties | Linked to transcytosis suppression |
| Caveolae-associated proteins | Mediate transcytosis | Targets for suppressing lipid transport |
How Is negative regulation of lipid transport across blood-brain barrier Regulated?
GO:1903001 is regulated by signaling pathways that control BBB transporter activity and barrier tightness. Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the BBB, demonstrating that nitric oxide signaling can modulate BBB transport. Inflammatory stimuli such as LPS activate NF-kB and induce miRNAs (miRNA-146a, miRNA-155) that mediate communication between the gut microbiome and the brain, potentially influencing BBB lipid transport. Metabolic status, such as feed restriction, alters cerebrospinal fluid and plasma metabolites, suggesting systemic metabolic regulation of brain lipid handling. Developmental programs also regulate lipid synthesis enzymes like NSDHL, which may indirectly affect lipid transport regulation.
negative regulation of lipid transport across blood-brain barrier and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MFSD2A | BBB permeability and lipid transport defects | Mfsd2a knockout mouse or endothelial cell KO |
| NF-kB | Neuroinflammation and gut-brain signaling | LPS-stimulated cell models with NF-kB reporters |
| miRNA-146a | Inflammatory BBB modulation | miRNA mimic/inhibitor in brain endothelial cells |
| miRNA-155 | Inflammatory BBB modulation | miRNA mimic/inhibitor in brain endothelial cells |
| NSDHL | Developmental lipid synthesis defects | NSDHL-deficient cell models and Bpa(1H)/+ mouse |
Neurovascular and BBB dysfunction
Loss of Mfsd2a, a key lysolipid transporter, increases BBB permeability and lipid transcytosis, linking impaired negative regulation of lipid transport to neurovascular dysfunction. Such barrier defects can expose the brain to unwanted blood-borne lipids and inflammatory mediators.
Neuroinflammation and gut-brain axis
LPS-stimulated NF-kB, miRNA-146a and miRNA-155 mediate molecular-genetic communication between the gastrointestinal microbiome and the brain, which can alter BBB function and lipid-related pathways. This connects GO:1903001 to neuroinflammatory conditions driven by peripheral signals.
Brain tumors and lipid nanomedicine
Lipid nanomedicine that simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling is being developed for medulloblastoma, illustrating how lipid transport and lipid-based delivery intersect with brain tumor therapy. Modulating BBB lipid transport could influence delivery and efficacy of such nanomedicines.
Metabolic and developmental disorders
Developmental expression of NSDHL and negative selection of NSDHL-deficient cells in the Bpa(1H)/+ mouse indicates that lipid synthesis and transport pathways are critical during development. Feed restriction alters cerebrospinal fluid metabolites, suggesting metabolic regulation of brain lipid handling.
From negative regulation of lipid transport across blood-brain barrier-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MFSD2A increase lipid transport across BBB? | MFSD2A knockout endothelial cells or mouse |
| Does nitric oxide signaling regulate BBB lipid transport? | NOS isoenzyme KO or inhibitor models |
| Does LPS-induced inflammation alter negative regulation of lipid transport? | LPS-stimulated brain endothelial cells with NF-kB/miRNA readouts |
| Does NSDHL deficiency affect lipid transport regulation? | NSDHL point-mutation or knockout cells |
| Can lipid nanomedicine modulate BBB lipid transport? | Medulloblastoma models treated with lipid nanomedicine |
| Does metabolic restriction change brain lipid handling? | Feed-restricted animal models with CSF metabolite profiling |
How to Study the negative regulation of lipid transport across blood-brain barrier Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify regulators of BBB lipid transport |
| Small RNA-seq | miRNA expression | Measure miRNA-146a/155 in inflammation |
| Lipid transport assay | Rate of lipid movement across BBB | Quantify negative regulation |
| Metabolomics | CSF and plasma metabolites | Assess metabolic regulation |
| Immunofluorescence | Protein localization at BBB | Study transporter distribution |
| Permeability assay | BBB leakiness | Evaluate barrier integrity |
| Western blot | Protein expression and signaling | Measure NF-kB and NOS activity |
| CRISPR screen | Identify genes regulating lipid transport | Discover new regulators of GO:1903001 |
Transcriptomic and miRNA profiling
RNA-seq and small RNA-seq can measure expression of BBB transporters, NF-kB targets and miRNAs such as miRNA-146a and miRNA-155 in response to LPS or other stimuli. These methods help identify regulators of GO:1903001.
Lipid transport assays
In vitro BBB models using brain endothelial cells can measure transport of fluorescent or radiolabeled lipids across monolayers. Such assays directly quantify the negative regulation of lipid transport.
Metabolomics of CSF and plasma
Metabolomic profiling of cerebrospinal fluid and plasma, as performed in feed-restricted dairy cows, can reveal systemic metabolic changes that influence brain lipid handling.
Imaging and permeability measurements
In vivo imaging and tracer permeability assays can assess BBB integrity and lipid transcytosis in models with Mfsd2a loss or nitric oxide modulation.
How CRISPR Can Be Used to Study GO:1903001 negative regulation of lipid transport across blood-brain barrier
Knockout
CRISPR knockout of MFSD2A in brain endothelial cells or mice can test whether loss of this transporter increases lipid transport across the BBB, thereby validating its role in GO:1903001. Knockout of NOS isoenzymes can reveal nitric oxide-dependent regulation of BBB transport.
Point Mutation
Point mutations in MFSD2A can dissect transporter activity versus regulatory functions, helping to separate lipid uptake from transcytosis suppression. Point mutations in NSDHL can model developmental lipid synthesis defects.
Knock-in
Knock-in of tagged MFSD2A or reporter alleles can enable live imaging of transporter localization and trafficking at the BBB. Knock-in of miRNA target sites can test regulation by miRNA-146a/155.
Overexpression
Overexpression of MFSD2A or its regulators can test whether increased negative regulation reduces lipid transport and tightens the BBB. Overexpression of NF-kB inhibitors can test inflammatory modulation of GO:1903001.
How EDITGENE Supports negative regulation of lipid transport across blood-brain barrier Research
Researchers studying negative regulation of lipid transport across blood-brain barrier-related genes often need to determine whether a candidate gene is causally involved in suppressing lipid transport or is merely correlated with barrier integrity. EDITGENE provides CRISPR-based cell models and screening services to establish causality and mechanism.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of lipid transport across blood-brain barrier research.
Frequently Asked Questions About negative regulation of lipid transport across blood-brain barrier
What is GO:1903001?
GO:1903001 is the Gene Ontology term for negative regulation of lipid transport across the blood-brain barrier, describing any process that stops, prevents or reduces lipid transport across the BBB.
What genes are involved in negative regulation of lipid transport across the blood-brain barrier?
Key genes include MFSD2A, which encodes a lysolipid transporter that suppresses transcytosis, as well as inflammatory mediators such as NF-kB and miRNAs.
How does MFSD2A regulate lipid transport at the BBB?
MFSD2A imports DHA-lysophosphatidylcholine and its loss increases BBB permeability and lipid transcytosis, indicating a role in negative regulation.
What is the role of nitric oxide in BBB lipid transport?
Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the BBB, showing that nitric oxide signaling modulates BBB transport.
How does inflammation affect lipid transport across the BBB?
LPS-stimulated NF-kB, miRNA-146a and miRNA-155 mediate gut-brain communication and can alter BBB-related pathways, potentially affecting lipid transport.
Can CRISPR be used to study GO:1903001?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models can test the causal role of genes such as MFSD2A in negative regulation of lipid transport.
What diseases are linked to impaired negative regulation of lipid transport across the BBB?
BBB dysfunction, neuroinflammation and brain tumors such as medulloblastoma are linked to altered lipid transport and barrier function.
What methods measure lipid transport across the BBB?
In vitro transport assays, permeability assays, imaging and metabolomics can measure lipid movement and barrier integrity.
Is NSDHL involved in lipid transport regulation?
NSDHL is a cholesterogenic enzyme whose developmental expression and negative selection in deficient cells suggest a role in lipid pathways relevant to the BBB.
How can lipid nanomedicine target brain tumors?
Lipid nanomedicine can simultaneously inhibit BRD4/PI3K and MDM2/XIAP signaling for medulloblastoma treatment, intersecting with BBB lipid transport.
Conclusion
GO:1903001, negative regulation of lipid transport across the blood-brain barrier, is a critical biological process that maintains brain lipid homeostasis and barrier integrity. Key regulators such as MFSD2A, nitric oxide signaling and inflammatory pathways control this process, and their dysfunction is linked to neurovascular and neuroinflammatory disease. CRISPR-based models and multi-omics methods provide powerful tools to dissect the mechanisms and identify therapeutic targets within this pathway.
References
- 1. Banks WA et al.. 2008. Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the blood-brain barrier.. Endocrinology 149(4):1514-23 PMID: 18187549
- 2. Sethi B et al.. 2025. Lipid nanomedicine simultaneously inhibits BRD4/PI3K and MDM2/XIAP signaling pathways for effective treatment of Medulloblastoma.. J Control Release 387:114266 PMID: 41005742
- 3. Wong BH et al.. 2020. Mfsd2a: A Physiologically Important Lysolipid Transporter in the Brain and Eye.. Adv Exp Med Biol 1276:223-234 PMID: 32705603
- 4. Alexandrov P et al.. 2019. Lipopolysaccharide-stimulated, NF-kB-, miRNA-146a- and miRNA-155-mediated molecular-genetic communication between the human gastrointestinal tract microbiome and the brain.. Folia Neuropathol 57(3):211-219 PMID: 31588707
- 5. Cunningham D et al.. 2009. Developmental expression pattern of the cholesterogenic enzyme NSDHL and negative selection of NSDHL-deficient cells in the heterozygous Bpa(1H)/+ mouse.. Mol Genet Metab 98(4):356-66 PMID: 19631568
- 6. Laeger T et al.. 2012. Effect of feed restriction on metabolites in cerebrospinal fluid and plasma of dairy cows.. J Dairy Sci 95(3):1198-208 PMID: 22365204
